Have your own idea? Try our Stock Screener
Polish (WIG) Pharma Industry Analysis
UpdatedApr 04, 2026
DataAggregated Company Financials
Companies6
- 7D4.0%
- 3M-3.3%
- 1Y-21.7%
- YTDn/a
The Pharma industry is up 4.0% in the last week, with Celon Pharma up 4.3%. In contrast, the industry has lost 22% in the last 12 months. As for the next few years, earnings are expected to grow by 66% per annum.
Industry Valuation and Performance
Has the Polish Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 04 Apr 2026 | zł1.3b | zł349.3m | -zł146,324,609.00 | 9.5x | -8.7x | 3.6x |
| Mon, 02 Mar 2026 | zł1.5b | zł349.2m | -zł146,238,953.00 | 10.1x | -10x | 4.2x |
| Wed, 28 Jan 2026 | zł1.4b | zł350.2m | -zł145,356,482.00 | 9.2x | -9.5x | 3.9x |
| Fri, 26 Dec 2025 | zł1.2b | zł350.2m | -zł145,356,482.00 | 8.8x | -8.4x | 3.5x |
| Sun, 23 Nov 2025 | zł1.3b | zł328.2m | -zł92,025,052.00 | 9.3x | -14x | 3.9x |
| Tue, 21 Oct 2025 | zł1.4b | zł327.7m | -zł93,055,146.00 | 9.9x | -15.5x | 4.4x |
| Thu, 18 Sep 2025 | zł1.4b | zł333.9m | -zł72,252,084.00 | 10.4x | -19.9x | 4.3x |
| Sat, 16 Aug 2025 | zł1.5b | zł335.2m | -zł73,494,581.00 | 14.4x | -20.2x | 4.4x |
| Mon, 14 Jul 2025 | zł1.5b | zł333.7m | -zł73,417,994.00 | 15.7x | -20x | 4.4x |
| Wed, 11 Jun 2025 | zł1.4b | zł333.7m | -zł73,417,994.00 | 13.3x | -19.2x | 4.2x |
| Fri, 09 May 2025 | zł1.6b | zł324.5m | -zł11,138,335.00 | 43.2x | -140.8x | 4.8x |
| Sun, 06 Apr 2025 | zł1.6b | zł324.0m | -zł12,792,856.00 | 43.7x | -124.4x | 4.9x |
| Tue, 04 Mar 2025 | zł1.6b | zł322.2m | -zł10,142,168.00 | 42.3x | -153.8x | 4.8x |
| Thu, 30 Jan 2025 | zł1.6b | zł318.9m | -zł9,295,998.00 | 42.1x | -170.6x | 5x |
| Sat, 28 Dec 2024 | zł1.7b | zł318.9m | -zł9,295,998.00 | 43.6x | -179.6x | 5.2x |
| Mon, 25 Nov 2024 | zł1.7b | zł431.2m | -zł14,248,195.00 | 44.2x | -119.9x | 4x |
| Wed, 23 Oct 2024 | zł1.9b | zł314.5m | -zł72,767,518.00 | 10.5x | -25.6x | 5.9x |
| Fri, 20 Sep 2024 | zł1.8b | zł317.3m | -zł60,178,104.00 | 12.1x | -30.4x | 5.8x |
| Sun, 18 Aug 2024 | zł1.8b | zł317.0m | -zł60,286,017.00 | 10.5x | -30x | 5.7x |
| Tue, 16 Jul 2024 | zł1.6b | zł310.8m | -zł61,217,640.00 | 11.9x | -26.1x | 5.1x |
| Thu, 13 Jun 2024 | zł1.1b | zł310.8m | -zł61,217,640.00 | 11x | -18.3x | 3.6x |
| Sat, 11 May 2024 | zł1.2b | zł310.9m | -zł43,157,065.00 | 12.9x | -27.2x | 3.8x |
| Mon, 08 Apr 2024 | zł1.2b | zł311.5m | -zł40,173,065.00 | 15.1x | -29x | 3.7x |
| Wed, 06 Mar 2024 | zł1.2b | zł311.5m | -zł40,173,065.00 | 15.8x | -29.2x | 3.8x |
| Fri, 02 Feb 2024 | zł1.2b | zł308.7m | -zł39,880,934.00 | 12.8x | -29.6x | 3.8x |
| Sun, 31 Dec 2023 | zł1.2b | zł308.7m | -zł39,880,934.00 | 11.7x | -29.4x | 3.8x |
| Tue, 28 Nov 2023 | zł1.1b | zł308.7m | -zł39,880,934.00 | 11.2x | -26.9x | 3.5x |
| Thu, 26 Oct 2023 | zł1.1b | zł302.0m | -zł42,933,291.00 | 11.2x | -25.6x | 3.6x |
| Sat, 23 Sep 2023 | zł1.2b | zł303.1m | -zł42,609,118.00 | 10.5x | -27.6x | 3.9x |
| Mon, 21 Aug 2023 | zł1.2b | zł287.0m | -zł53,882,152.00 | 11.3x | -22.3x | 4.2x |
| Wed, 19 Jul 2023 | zł1.2b | zł278.4m | -zł53,806,540.00 | 36.5x | -22.8x | 4.4x |
| Fri, 16 Jun 2023 | zł1.2b | zł283.9m | -zł53,238,141.00 | 35.1x | -22.7x | 4.2x |
| Sun, 14 May 2023 | zł1.1b | zł275.3m | -zł51,408,128.00 | 9.4x | -20.9x | 3.9x |
| Tue, 11 Apr 2023 | zł1.1b | zł273.2m | -zł44,427,333.00 | 8.9x | -25.7x | 4.2x |
Price to Earnings Ratio
-25.7x
Current Industry PE
- Investors are pessimistic on the Polish Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 8.5% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does Polish Pharma compare with similar industries?
| PL Market | 4.78% | |
| Healthcare | 0.64% | |
| Pharma | 4.01% | |
| Pharma | 4.01% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| CLN Celon Pharma | zł20.30 | 4.3% +zł45.2m | -18.3% | PS4.8x | |
| MOC Molecure | zł5.28 | 2.7% +zł2.9m | -39.3% | PS18.6x | |
| GRZ Green Zebras Spolka Akcyjna | zł8.40 | 9.1% +zł1.1m | -14.3% | PS10.5x | |
| CBD Cannabis Poland | zł0.20 | 1.4% +zł138.8k | -42.7% | PS46.4x |